A Randomized Phase II Clinical Trial of Nab-Paclitaxel and Carboplatin Compared With Gemcitabine and Carboplatin as First-line Therapy in Advanced Squamous Cell Carcinoma of Lung
Albumin-bound paclitaxel(nab-P) utilizes the albumin binding proteins,such as
(gp60)/caveolin-1 (CAV1) and SPARC(secreted protein acidic and rich in cysteine), achieving
high intratumoral paclitaxel accumulation. It is reported that CAV1 is overexpressed in
squamous cell cancer(SQC), so it is possible that nab-PC is more highly active than GC in
SQC of lung.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate(ORR)
ORR is evaluated after at most 6 cycles of chemotherapy, which may cost 18 weeks.
Wu Yilong, professor
Guangdong General Hospital
China: Food and Drug Administration